<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Borderline ovarian tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Borderline ovarian tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Borderline ovarian tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lee-may Chen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Borderline tumors of the ovary (also called tumors of low malignant potential) are a heterogeneous group of lesions defined histologically by atypical epithelial proliferation without stromal invasion [<a href="#rid1">1</a>]. The behavior of these tumors is distinct from low-grade ovarian carcinoma, and they are considered a distinct clinical entity.</p><p>The epidemiology, diagnosis, and treatment of borderline ovarian tumors are reviewed here. Ovarian cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/83397.html" rel="external">"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"</a> and  <a class="medical medical_review" href="/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors"</a> and  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a> and  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H9972461"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Borderline ovarian epithelial neoplasms are noninvasive neoplasms that occasionally have intraperitoneal spread [<a href="#rid2">2</a>]. This group of neoplasms exhibits behavior that is intermediate between benign cystadenomas and invasive carcinomas. These have been referred to by different terms, including: borderline, atypical proliferative, and tumors of low malignant potential. Borderline neoplasm is currently the most widely used designation by pathologists, gynecologists, and oncologists, and has been adopted into the World Health Organization (WHO) classification [<a href="#rid3">3</a>].</p><p>Borderline tumors account for 14 to 15 percent of all primary ovarian neoplasms [<a href="#rid4">4</a>].</p><p>Borderline tumors occur in a variety of histologies, as in epithelial ovarian carcinoma [<a href="#rid5">5,6</a>]. The majority of cases are serous or mucinous. Rarely, endometrioid, clear-cell, or transitional cell (Brenner) borderline tumors are found.</p><p>The histopathology of serous and mucinous borderline ovarian tumors is discussed briefly here. The histopathology of borderline ovarian neoplasms is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3241.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology", section on 'Overview of borderline neoplasms'</a>.)</p><p class="headingAnchor" id="H2228073929"><span class="h2">Serous borderline tumors</span><span class="headingEndMark"> — </span>Among ovarian borderline tumors, approximately 65 to 70 percent are serous histology, and borderline tumors account for an estimated 15 to 20 percent of all ovarian serous neoplasms [<a href="#rid6">6-8</a>].</p><p>In the vast majority of patients, serous borderline tumors are confined to the ovary at the time of diagnosis [<a href="#rid9">9,10</a>]. Approximately 70 percent of cases are diagnosed at stage I [<a href="#rid11">11</a>]. However, up to 50 percent of the time, serous borderline tumors are bilateral [<a href="#rid9">9,10</a>].</p><p>Micropapillary features are present in 10 to 15 percent of serous borderline tumors, as well as in other types of benign and malignant serous ovarian tumors. The presence of micropapillary features is associated with an increased likelihood of both invasive peritoneal implants and of recurrence [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2228074101"><span class="h2">Mucinous borderline tumors</span><span class="headingEndMark"> — </span>Mucinous tumors are the other common histologic type of borderline ovarian neoplasm; they account for approximately 11 percent of borderline tumors [<a href="#rid13">13</a>]. At diagnosis, the great majority are stage I (100 percent in one study of 15 patients [<a href="#rid13">13</a>]). </p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Based on registry data from the United States, Denmark, and Sweden, the estimated incidence of these tumors ranged from 1.8 to 5.5 per 100,000 women per year [<a href="#rid4">4,14,15</a>]. Some data suggest that the incidence is increasing [<a href="#rid16">16</a>]. As an example, a Danish study reported that the incidence of borderline ovarian tumors increased from 2.6 to 5.5 per 100,000 person-years between 1978 and 2006 [<a href="#rid15">15</a>].</p><p>Approximately one-third of patients diagnosed with a borderline ovarian tumor are younger than 40 years of age [<a href="#rid4">4,6</a>]. This makes issues related to ovarian function and fertility preservation of increased importance. (See <a class="local">'Future pregnancy'</a> below and <a class="local">'Hormone therapy'</a> below.)</p><p>The majority of cases are diagnosed at stage I. As an example, in one literature review including 948 cases, 70 percent presented as stage I, 10 percent presented as stage II, 19 percent presented as stage III, and less than 1 percent presented as stage IV [<a href="#rid11">11</a>].</p><p>Some data suggest that infertility or infertility treatments are associated with an increased risk of borderline tumors, but these data are limited by methodologic issues and a small number of cases. Regarding infertility, a meta-analysis of eight case-control studies reported a significant increase in the risk of borderline tumors in patients with an unknown cause of infertility (odds ratio [OR] 1.86, 95% CI 1.26-2.74) [<a href="#rid17">17</a>].</p><p>Data are mixed regarding the association between ovulation induction and borderline ovarian tumors. A systematic review including four observational studies found that use of any infertility drug was associated with a two- to threefold increase in the risk of a borderline ovarian tumor [<a href="#rid18">18</a>]. In contrast, a subsequent Danish population-based study (n = 142 cases of borderline tumors) found no increase in risk associated with fertility drug use; however, the study lacked sufficient statistical power [<a href="#rid19">19</a>].</p><p>The relationship between <em>BRCA</em> gene mutations and borderline ovarian tumors is uncertain. It appears that the prevalence of <em>BRCA</em> mutations is lower among patients with borderline tumors than in patients with invasive ovarian carcinoma [<a href="#rid20">20-22</a>]. As an example, in one study of Jewish subjects with ovarian neoplasms, the rate of <em>BRCA</em> mutations was higher in those with stage I ovarian carcinoma (24 percent of 256 patients) than in those with borderline tumors (4 percent of 233 patients) [<a href="#rid23">23</a>].</p><p>Data are mixed regarding whether postmenopausal hormone therapy is associated with an increased risk of borderline tumors. A Danish national database study including 703 patients with borderline ovarian tumors reported that four years of use of estrogen or estrogen and progestin therapy was associated with a 1.3- to 1.5-fold increased risk of a borderline tumor [<a href="#rid24">24</a>]. In contrast, two other retrospective studies found limited or no association for most patients. One study found a significant increase in borderline tumors with two to three years of use, but not for other durations [<a href="#rid25">25</a>]. Another study found a significant increase in risk only with unopposed estrogen in patients who developed serous tumors, but not with combined estrogen and progestin therapy in either serous or mucinous tumors [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H453805524"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of borderline ovarian tumors is the same as for other adnexal masses. Some patients are asymptomatic at presentation (14 percent in one study) [<a href="#rid27">27</a>]. Symptoms may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic or abdominal pain or pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspareunia</p><p></p><p>In contrast with patients with ovarian carcinoma, those with borderline tumors are unlikely to present with ascites, bowel obstruction, pleural effusion, or venous thromboembolism.</p><p>In asymptomatic patients, borderline tumors may be detected incidentally as a mass noted on pelvic examination or imaging performed for another indication. In our experience, we suspect a borderline tumor in a younger patient with a relatively asymptomatic ovarian cyst that has evidence of internal papillary growth on ultrasound.</p><p>The clinical presentation of patients with an adnexal mass or ovarian cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H2228074175"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The diagnostic evaluation of a borderline ovarian tumor is the same as for ovarian carcinoma, with the distinction that serum CA 125 does not appear to be a useful test.</p><p>This section will review aspects of the evaluation that are particular to borderline tumors. The evaluation and diagnosis of ovarian cancer and the approach to an adnexal mass are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>.)</p><p>In general, the diagnostic evaluation includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical history</strong> – Symptoms and risk factors  (<a class="graphic graphic_table graphicRef59585" href="/d/graphic/59585.html" rel="external">table 1</a>) associated with an ovarian neoplasm and a medical and surgical history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The examination may demonstrate fullness in the pelvis or a palpable ovarian mass. However, neither of these are specific to the diagnosis of a borderline ovarian tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pelvic and abdominal imaging</strong> – A transvaginal ultrasound is typically the first-line imaging study to evaluate an adnexal mass. If an ovarian borderline tumor or carcinoma is suspected, abdominal imaging is performed if metastatic disease is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical evaluation</strong> – Surgical exploration is typically required to obtain a specimen for histologic diagnosis. Frozen section is often used intraoperatively.</p><p></p><p class="headingAnchor" id="H453805555"><span class="h2">Pelvic ultrasound</span><span class="headingEndMark"> — </span>There are no sonographic features that differentiate an ovarian borderline tumor from a benign or invasive ovarian neoplasm. The sonographic appearance of borderline ovarian tumors ranges from unilocular cysts to masses with both solid and fluid components; papilla are common [<a href="#rid28">28-31</a>]. (See  <a class="medical medical_review" href="/d/html/3208.html" rel="external">"Adnexal mass: Ultrasound categorization"</a>.)</p><p class="headingAnchor" id="H453805836"><span class="h2">Tumor markers</span><span class="headingEndMark"> — </span>The CA 125 tumor marker does not appear to be useful in the detection of a borderline ovarian tumor. This was the finding in a retrospective series of over 1000 patients with borderline tumors [<a href="#rid32">32</a>]. Almost one-half of all patients had a normal CA 125 level, and less than 25 percent had levels above 100 units/mL. If the CA 125 level is high, ovarian cancer should be suspected. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Role of tumor markers and multimodal tests'</a>.)</p><p class="headingAnchor" id="H3548667"><span class="h2">Surgical exploration</span><span class="headingEndMark"> — </span>Borderline tumors present as an adnexal mass suspicious for ovarian cancer. The decision to proceed with surgery is based upon this indication.</p><p>Intraoperatively, in our experience, the gross appearance of a borderline tumor includes papillary excrescences (an appearance similar to cauliflower or coral).</p><p>As with other suspicious adnexal masses, the goal is to confirm the histology and proceed with the procedure that preserves fertility and ovarian function, if possible. If an ovarian mass is suspected to be malignant, the standard procedure is to remove the ovary intact and send it for frozen section. However, if a mass is suspected to be benign or borderline, a cystectomy may be performed. If both ovaries are involved, the lesion that appears more suspicious should be removed and sent for frozen pathology.</p><p>If the histology shows a borderline neoplasm or invasive disease, staging is performed, which may include ovarian conservation. In any surgery for an adnexal mass that has the potential to be borderline or malignant, preoperative counseling should include discussion of patient preferences and options regarding ovarian conservation versus complete staging. (See <a class="local">'Complete staging versus conservative surgery'</a> below.) </p><p class="headingAnchor" id="H2228074579"><span class="h3">Frozen section</span><span class="headingEndMark"> — </span>Frozen section is commonly performed intraoperatively, and the information is used to help determine the extent of the surgical procedure. A meta-analysis of 18 studies on the diagnostic accuracy of frozen section results of ovarian pathology found generally good sensitivity (65 to 100 percent) and excellent specificity (&gt;99 percent) when compared with the final histologic diagnosis [<a href="#rid33">33</a>]. Factors that lower the sensitivity of frozen section diagnosis of malignancy include large neoplasms, mucinous tumors (which have more histologic variation), and borderline tumors, since all require a large number of sections to exclude the presence of a focal area of invasive disease.</p><p class="headingAnchor" id="H453805687"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Borderline ovarian neoplasm is a histologic diagnosis. This evaluation is performed following surgical removal of an ovary. Infrequently, peritoneal spread is present, and the diagnosis may be made based upon biopsies of the peritoneum at the time of surgery.</p><p class="headingAnchor" id="H9972522"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of borderline ovarian neoplasm is the same as for ovarian cancer and other adnexal masses. (See  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>The first step in the evaluation of an adnexal mass is to confirm the presence and anatomic location of the mass with pelvic imaging, usually ultrasound. The differential diagnosis of an adnexal mass is shown in the table and discussed in detail separately  (<a class="graphic graphic_table graphicRef107713" href="/d/graphic/107713.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H10"><span class="h1">STAGING AND SURGICAL TREATMENT</span><span class="headingEndMark"> — </span>The staging system for borderline ovarian tumors is similar to that for other invasive ovarian carcinomas and carcinoma of the fallopian tube or peritoneum  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 3</a>). </p><p>The complete staging procedure for patients in whom future pregnancy is not desired includes total hysterectomy and bilateral salpingo-oophorectomy (BSO), peritoneal washing, omentectomy, and resection of grossly visible metastases. More conservative surgery may be performed in patients in whom future pregnancy is desired. </p><p>In our practice, we do not perform lymphadenectomy in patients with borderline tumors. The low prognostic utility of lymph node sampling was illustrated in a meta-analysis of 97 studies including over 4000 patients with ovarian tumors of low malignant potential that reported 98 percent survival at 6.5 years in patients with lymph node involvement [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H1028405"><span class="h2">Complete staging versus conservative surgery</span><span class="headingEndMark"> — </span>The choice of full staging or ovary-conserving surgery should be individualized. Approximately one-third of borderline ovarian tumors occur in patients younger than 40 years of age, and many young patients desire to conserve at least one ovary to preserve fertility and/or avoid the symptoms and effects of premature menopause [<a href="#rid4">4,6</a>]. Ovarian borderline tumors are not a common condition and most data derive from retrospective cases series of less than 100 patients.</p><p>The disease has a good prognosis (stage I five-year survival is 99 percent) and unilateral salpingo-oophorectomy (USO) appears to be an option for patients with unilateral disease [<a href="#rid36">36-39</a>]. Some data suggest that ovarian cystectomy is also acceptable. (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a> and <a class="local">'Survival'</a> below.)</p><p>The overall risk of recurrence after conservative surgery ranges from 7 to 30 percent [<a href="#rid36">36</a>], and recurrences typically show borderline histology, not invasive carcinoma [<a href="#rid37">37</a>]. The efficacy of conservative surgery in early-stage disease was best illustrated in a systematic review and meta-analysis of 120 mostly retrospective studies [<a href="#rid40">40</a>]. For patients with stage I ovarian borderline tumors treated with either USO or ovarian cystectomy, with an average follow-up of three to six years, the borderline recurrence rate was 13 percent, recurrence with malignant disease was 1.6 percent, and the death rate was 0.5 percent. This study was limited because it combined data for USO and cystectomy.</p><p>Some data suggest that USO is more effective than ovarian cystectomy, especially if the margins are positive or the resection is incomplete [<a href="#rid36">36,41,42</a>]. The two procedures were compared in a retrospective series of 193 patients with borderline ovarian tumors that was included in the systematic review described above [<a href="#rid38">38,40</a>]. In this study, the five-year disease-free survival rate for all patients was approximately 95 percent. The recurrence rate was higher and recurrence occurred sooner after cystectomy. For USO, 10 of 146 (7 percent) patients had recurrences and the median time to recurrence was 4.8 years (range 1.7 to 7.2 years); two of the recurrences were malignant disease. For cystectomy, 11 of 47 (23 percent) patients recurred and the median time to recurrence was 2.6 years (range 0.3 to 14 years); there were no malignant recurrences.</p><p>Recurrence of borderline disease requires surgical resection, typically full staging. If no malignant disease is present, borderline recurrences are not associated with mortality. In some cases, even after a recurrence, the uterus and one ovary or part of an ovary may be conserved to retain fertility.</p><p>For patients with advanced-stage disease, full staging with total hysterectomy and BSO appears to be more effective, and the risk of progression to invasive disease is clinically significant. In a study of patients with stage I to III disease, tumor recurrence rates after total abdominal hysterectomy and BSO (TAH-BSO), adnexectomy, and cystectomy were 6, 15, and 36 percent, respectively [<a href="#rid37">37</a>]. In a systematic review including 14 studies with 137 patients with stage II to IV serous borderline tumors, there were eight (6 percent) reports of invasive recurrences.</p><p>The advantages of comprehensive staging are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection of advanced-stage disease</strong> – If comprehensive staging is not performed, it is possible that pelvic or peritoneal spread may be missed. For presumed stage I serous borderline tumors, if a comprehensive staging procedure is performed after an initial nonstaging procedure (eg, simple oophorectomy), upstaging is not uncommon (12 to 47 percent) [<a href="#rid43">43,44</a>]. For mucinous tumor, presumed stage I disease typically is stage I.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection of occult invasion</strong> – Some cases that are thought to be borderline based upon frozen section will turn out to be invasive carcinoma. In such cases, the patient will require a second procedure if comprehensive staging was not performed as the initial procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Better information for prognostic counseling.</p><p></p><p>For patients in whom complete staging was not performed because the diagnosis of borderline ovarian cancer was made only at the time of final pathology review, imaging (with computed tomography [CT] with contrast) may be useful to assess for residual disease and to identify those patients in whom additional surgery is warranted. </p><p class="headingAnchor" id="H16134900"><span class="h3">Desire fertility preservation</span><span class="headingEndMark"> — </span>For patients with an apparent unilateral stage I borderline ovarian tumor (based upon preoperative and intraoperative imaging and examination) who wish to preserve fertility or endocrine function, we suggest salpingo-oophorectomy of the affected ovary, pelvic washings, an omental biopsy, and a biopsy of any peritoneal lesions rather than full staging for ovarian cancer. All macroscopic disease should be resected. Appendectomy is performed for mucinous tumors.</p><p>Borderline tumors may be discovered inadvertently in a patient undergoing surgery for a presumed benign ovarian mass. If the patient may desire future reproduction, conservative surgery is performed. If surgical expertise for staging is available, additional biopsies of omentum or other peritoneal lesions may be performed. Peritoneal washings should be sent and appendectomy should be performed in patients with mucinous tumors. If the final pathology demonstrates a more aggressive (invasive) lesion, additional surgical staging may be performed at a later time. If future reproduction is not desired, full staging may also be considered.</p><p>It is controversial whether patients who have fertility-conserving surgery should undergo removal of a remaining ovary or uterus upon completion of childbearing. The National Comprehensive Cancer Network (NCCN) advises consideration of completion surgery upon completion of childbearing for patients with a remaining ovary [<a href="#rid45">45</a>]. Based on the low recurrence rate of borderline tumors and the low risk of malignancy, in our practice, we do not routinely perform completion surgery in these patients [<a href="#rid10">10,11</a>].</p><p>In addition, if an ovarian borderline tumor or malignancy is suspected preoperatively, patients who desire to retain fertility should be offered a consultation with a fertility specialist to review options, including embryo or oocyte cryopreservation. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p class="headingAnchor" id="H16134989"><span class="h4">Bilateral tumors</span><span class="headingEndMark"> — </span>For patients with bilateral ovarian borderline tumors, oophorectomy on one side and cystectomy on the other is the usual treatment approach.</p><p>An ultraconservative approach using bilateral cystectomy was found to be effective and had better fertility outcomes in a randomized trial of patients with bilateral ovarian borderline tumors (n = 32); most patients had stage I disease (three had stage II to IV) [<a href="#rid46">46</a>]. At 81-month follow-up, there was no significant difference in the recurrence rate for patients who underwent bilateral cystectomy compared with standard surgery, unilateral oophorectomy combined with contralateral cystectomy (60 versus 59 percent). Recurrence occurred sooner in the bilateral cystectomy group (16 versus 48 months), and multiple recurrences were more likely (23 versus 0 percent). There were no invasive recurrences. Fertility outcomes were better following bilateral cystectomy (pregnancy rates: 93 versus 53 percent). The recurrence rate in this study was high, likely due to the inclusion of patients with advanced disease.</p><p class="headingAnchor" id="H1028353"><span class="h3">Advanced disease</span><span class="headingEndMark"> — </span>Complete staging with total hysterectomy-BSO is typically performed for patients with stage II or higher disease. However, patients with advanced ovarian borderline tumors may retain fertility, particularly if one ovary is unaffected.</p><p class="headingAnchor" id="H16134825"><span class="h3">Do not desire fertility preservation</span><span class="headingEndMark"> — </span>For patients with borderline ovarian tumors who are postmenopausal or who do not wish to preserve fertility or endocrine function, a full staging procedure with total hysterectomy-BSO is performed. Informed consent should include counseling premenopausal patients about the symptoms, effects, and management options for premature menopause. (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a> and <a class="local">'Hormone therapy'</a> below.) </p><p class="headingAnchor" id="H1027761"><span class="h2">Laparotomy versus laparoscopy</span><span class="headingEndMark"> — </span>A laparoscopic approach has not been evaluated in randomized trials. In general, retrospective series have reported that cyst rupture was more likely and complete staging was less likely with laparoscopic surgery than laparotomy, but there was no difference in recurrence rate [<a href="#rid47">47-49</a>].</p><p class="headingAnchor" id="H14"><span class="h1">CHEMOTHERAPY</span><span class="headingEndMark"> — </span>Chemotherapy is rarely indicated for patients with borderline ovarian tumors. While most clinicians would agree that there is no advantage for chemotherapy in patients with early-stage, completely resected disease [<a href="#rid50">50</a>], its use for those with more advanced-stage disease is controversial.</p><p>Some retrospective studies suggest benefit for adjuvant chemotherapy following optimal debulking of stage III or IV borderline tumors [<a href="#rid51">51,52</a>], while others do not [<a href="#rid53">53,54</a>]. The largest of these reports consisted of 80 patients with stage II to IV serous borderline tumors [<a href="#rid54">54</a>]. No patient with stage II disease received adjuvant chemotherapy, while of the 65 patients with stage III or IV disease, 17 received adjuvant chemotherapy (with a variety of both intravenous and intraperitoneal regimens) and the remainder did not. None of the patients with residual disease after initial surgery received chemotherapy. Major findings were that:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with chemotherapy was associated with a lower progression-free survival rate at three years compared with no treatment (71 versus 90 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a median follow-up of 4.8 years, 17 (21 percent) developed recurrent disease, all of whom had metastasis to the omentum or to multiple sites at original presentation. The sites of recurrent disease included pelvis in 15, omentum in 29, isolated lymph nodes in two, axilla in one, and multiple sites in 32.</p><p></p><p>Thus, the use of chemotherapy did not appear to impact the risk of recurrence. Given the apparently favorable outcome of advanced-stage serous borderline tumors, and the fact that a survival benefit from administration of adjuvant chemotherapy has not been clearly demonstrated, most clinicians recommend chemotherapy after aggressive surgical debulking only if invasive implants are identified [<a href="#rid55">55</a>].</p><p>Borderline ovarian tumors, which are on the same genetic spectrum as low-grade serous carcinomas of the ovary, may be responsive to other hormonal or other targeted therapies, beyond traditional chemotherapy; however, these therapies are investigational. </p><p class="headingAnchor" id="H15"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H16"><span class="h2">Posttreatment surveillance</span><span class="headingEndMark"> — </span>There is no high quality evidence to support one posttreatment surveillance strategy over another. The Society of Gynecologic Oncology (SGO) and National Comprehensive Cancer Network (NCCN) have each published guidelines for posttreatment surveillance for patients with ovarian cancer [<a href="#rid56">56,57</a>], and it is reasonable to extrapolate them for patients with borderline tumors. These surveillance guidelines are discussed separately. (See  <a class="medical medical_review" href="/d/html/17007.html" rel="external">"Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Post-treatment surveillance'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Future pregnancy</span><span class="headingEndMark"> — </span>There is no evidence that patients who undergo fertility-sparing surgery and become pregnant are at increased risk of mortality from disease progression [<a href="#rid37">37,58-65</a>]. Fertility treatments, such as ovulation induction, also appear to be safe, if indicated [<a href="#rid63">63,66,67</a>].</p><p>A systematic review of 120 studies reported a 54 percent pregnancy rate at three to six years in patients treated conservatively for borderline tumors [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Hormone therapy</span><span class="headingEndMark"> — </span>There are no data regarding the risk of recurrence of borderline tumor with use of postmenopausal hormone therapy, although some data suggest that hormone therapy is a risk factor for developing the disease. In our practice, we offer postmenopausal patients hormone therapy after comprehensive counseling about risks and benefits. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p>The rare endometrioid tumor of low malignant potential, just like endometriosis, could theoretically (and anecdotally) be stimulated to grow by estrogens; one could test estrogen receptors and if they are highly positive, one might avoid estrogens in these tumors.</p><p>Postmenopausal hormone therapy in ovarian cancer survivors is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/17007.html" rel="external">"Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Menopause'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Higher-stage disease is the major risk factor associated with recurrence; it is less clear whether the presence of invasive peritoneal implants, histologic subtype (eg, serous borderline with micropapillary pattern, mucinous peritoneal), DNA aneuploidy, and/or microinvasion affect overall prognosis [<a href="#rid68">68-72</a>]. </p><p class="headingAnchor" id="H20"><span class="h2">Survival</span><span class="headingEndMark"> — </span>The prognosis depends upon the stage and histologic features of the tumor, but is generally good  (<a class="graphic graphic_table graphicRef72025" href="/d/graphic/72025.html" rel="external">table 4</a>). A series of 2818 patients with ovarian tumors of low malignant potential from the Surveillance, Epidemiology, and End Results (SEER) database from the National Cancer Institute reported the following 5- and 10-year relative survival rates [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I</strong> – 99 and 97 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II</strong> – 98 and 90 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III</strong> – 96 and 88 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV</strong> – 77 and 69 percent, respectively</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Progression</span><span class="headingEndMark"> — </span>The risk of malignant transformation is unclear. For example, a serous ovarian tumor of low malignant potential may recur with similar histology or as a low-grade serous carcinoma, or both histologies may be present. In one series of 339 patients with borderline tumors, only 2 percent went on to develop invasive carcinoma [<a href="#rid10">10</a>]. Progression to invasive cancer may represent true transformation, de novo development of an ovarian cancer, or a peritoneal cancer.</p><p>There is increasing evidence that the pathogenesis of low-grade serous carcinomas and of serous tumors of low malignant potential involves similar genes and pathways, and is distinct from that of high-grade serous carcinomas. (See  <a class="medical medical_review" href="/d/html/3241.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology", section on 'Overview of borderline neoplasms'</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">MANAGEMENT OF RECURRENCE</span><span class="headingEndMark"> — </span>The optimal approach to management of recurrent disease has not been determined, but appears to be surgical cytoreduction, which is associated with improved survival in observational series [<a href="#rid74">74-78</a>]. As an example, one retrospective series of 21 patients with recurrent serous borderline tumors (micropapillary pattern) reported median overall survival of 61 months with optimal resection versus 26 months with suboptimal resection [<a href="#rid77">77</a>]. Five patients did not undergo secondary surgery and were treated with chemotherapy alone; their median survival was 30 months.</p><p class="headingAnchor" id="H1693338265"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119533.html" rel="external">"Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H8871446"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian borderline tumors (also called tumors of low malignant potential) are a heterogeneous group of lesions defined histologically by atypical epithelial proliferation without stromal invasion. These tumors account for 14 to 15 percent of ovarian epithelial tumors. (See <a class="local">'Introduction'</a> above and <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of borderline tumors are serous. Approximately 75 percent of patients are diagnosed with stage I disease; 25 to 50 percent of tumors are bilateral. Mucinous tumors are the other common cellular type; 90 percent are stage I and less than 10 percent are bilateral. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The estimated incidence of these tumors ranges from 1.8 to 5.5 per 100,000 women per year. Approximately one-third of patients diagnosed with a borderline ovarian tumor are younger than 40 years of age. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients present with an asymptomatic adnexal mass noted either on bimanual examination or as an incidental finding on sonography; however, symptoms (eg, abdominal/pelvic pain or dyspareunia) may occur, as with any adnexal mass. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no sonographic features strongly suggestive of borderline histology. Sonographic appearance ranges from unilocular cysts to masses with both solid and fluid components; papilla are common. Measurement of CA 125 does not reliably predict borderline histology. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of these neoplasms is based upon histopathologic examination. Frozen section is commonly performed intraoperatively, and the information is used to help determine the extent of the surgical procedure. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Borderline tumors are staged using the same criteria as other ovarian neoplasms  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 3</a>). Most patients present with stage I disease (approximately 70 percent); stage II to IV disease is relatively infrequent. (See <a class="local">'Staging and surgical treatment'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete staging with total hysterectomy and bilateral salpingo-oophorectomy (BSO) is required for patients with stage II or higher disease. For patients with borderline ovarian tumors who are postmenopausal or who do not wish to preserve fertility or endocrine function, a full staging procedure with total hysterectomy-BSO is performed. Informed consent should include counseling premenopausal patients about the symptoms, effects, and management options for premature menopause. (See <a class="local">'Advanced disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an apparent unilateral stage I borderline ovarian tumor, we suggest salpingo-oophorectomy of the affected ovary, pelvic washings, an omental biopsy, and a biopsy of any peritoneal lesions rather than full staging for ovarian cancer (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Appendectomy is performed for mucinous tumors. BSO is required in patients with bilateral borderline ovarian tumors. (See <a class="local">'Desire fertility preservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of adjuvant chemotherapy is controversial; there is no advantage to treatment of patients with early-stage disease. While patients with more advanced disease may be rendered disease-free, survival benefit related to the administration of adjuvant chemotherapy has not been clearly demonstrated. We recommend chemotherapy after aggressive surgical debulking only if invasive implants are identified (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence that estrogens stimulate the growth of borderline serous or mucinous tumors of the ovary, or that their use in any way adversely affects the likelihood of relapse or survival. (See <a class="local">'Hormone therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Borderline tumors have an excellent prognosis (stage I five-year survival is 99 percent). The risk of malignant transformation is unclear. Progression to invasive cancer may represent true transformation, de novo development of an ovarian cancer, or a peritoneal cancer. (See <a class="local">'Survival'</a> above and <a class="local">'Progression'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Blaustein's pathology of the female genital tract, 5th, Kurman RJ (Ed), Springer Verlag, New York 2002. p.791.</li><li><a class="nounderline abstract_t">Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003; 17:909.</a></li><li><a class="nounderline abstract_t">Karseladze AI. [WHO histological classification of ovarian tumors. Geneva, 1999 (R.E.Scully, L.H.Sobin]. Arkh Patol 2005; Suppl:1.</a></li><li><a class="nounderline abstract_t">Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008; 123:1897.</a></li><li><a class="nounderline abstract_t">Trimble CL, Trimble EL. Ovarian tumors of low malignant potential. Oncology (Williston Park) 2003; 17:1563.</a></li><li><a class="nounderline abstract_t">Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014; 24:S5.</a></li><li><a class="nounderline abstract_t">Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18 Suppl 2:S33.</a></li><li><a class="nounderline abstract_t">Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 2006; 49:517.</a></li><li><a class="nounderline abstract_t">Pecorelli, S, Odicino, et al. FIGO annual report of the results of treatment in gynaecological cancer. Carcinoma of the ovary. J Epidemiol Biostat 1998; 3:75.</a></li><li><a class="nounderline abstract_t">Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19:2658.</a></li><li><a class="nounderline abstract_t">Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006; 100:185.</a></li><li><a class="nounderline abstract_t">Sood AK, Abu-Rustum NR, Barakat RR, et al. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol 2005; 97:916.</a></li><li><a class="nounderline abstract_t">Lazarou A, Fotopoulou C, Coumbos A, et al. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. Anticancer Res 2014; 34:6725.</a></li><li><a class="nounderline abstract_t">Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002; 95:2380.</a></li><li><a class="nounderline abstract_t">Hannibal CG, Huusom LD, Kjaerbye-Thygesen A, et al. Trends in incidence of borderline ovarian tumors in Denmark 1978-2006. Acta Obstet Gynecol Scand 2011; 90:305.</a></li><li><a class="nounderline abstract_t">Yahata T, Banzai C, Tanaka K, Niigata Gynecological Cancer Registry. Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res 2012; 38:645.</a></li><li><a class="nounderline abstract_t">Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.</a></li><li><a class="nounderline abstract_t">Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2013; :CD008215.</a></li><li><a class="nounderline abstract_t">Bjørnholt SM, Kjaer SK, Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod 2015; 30:222.</a></li><li><a class="nounderline abstract_t">Bjørge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004; 91:1829.</a></li><li><a class="nounderline abstract_t">Maehle L, Apold J, Paulsen T, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res 2008; 14:7569.</a></li><li><a class="nounderline abstract_t">Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807.</a></li><li><a class="nounderline abstract_t">Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005; 97:780.</a></li><li><a class="nounderline abstract_t">Mørch LS, Løkkegaard E, Andreasen AH, et al. Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control 2012; 23:113.</a></li><li><a class="nounderline abstract_t">Mills PK, Riordan DG, Cress RD, Goldsmith DF. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005; 29:124.</a></li><li><a class="nounderline abstract_t">Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83:575.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.</a></li><li><a class="nounderline abstract_t">Exacoustos C, Romanini ME, Rinaldo D, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005; 25:50.</a></li><li><a class="nounderline abstract_t">Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004; 18:71.</a></li><li><a class="nounderline abstract_t">Valentin L, Ameye L, Testa A, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006; 102:41.</a></li><li><a class="nounderline abstract_t">Yazbek J, Raju KS, Ben-Nagi J, et al. Accuracy of ultrasound subjective 'pattern recognition' for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 2007; 29:489.</a></li><li><a class="nounderline abstract_t">Ochiai, K, Shinozaki, et al. A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1998; 17:A1429.</a></li><li><a class="nounderline abstract_t">Geomini P, Bremer G, Kruitwagen R, Mol BW. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 2005; 96:1.</a></li><li><a class="nounderline abstract_t">Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539.</a></li><li><a class="nounderline abstract_t">Lesieur B, Kane A, Duvillard P, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011; 204:438.e1.</a></li><li><a class="nounderline abstract_t">Boran N, Cil AP, Tulunay G, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005; 97:845.</a></li><li><a class="nounderline abstract_t">Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75:92.</a></li><li><a class="nounderline abstract_t">Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006; 103:841.</a></li><li><a class="nounderline abstract_t">Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003; 24:223.</a></li><li><a class="nounderline abstract_t">Daraï E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19:151.</a></li><li><a class="nounderline abstract_t">Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72:775.</a></li><li><a class="nounderline abstract_t">Yokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 2006; 94:1586.</a></li><li><a class="nounderline abstract_t">Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16:513.</a></li><li><a class="nounderline abstract_t">Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 2004; 100:1145.</a></li><li class="breakAll">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#site (Accessed on March 20, 2015).</li><li><a class="nounderline abstract_t">Palomba S, Zupi E, Russo T, et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod 2007; 22:578.</a></li><li><a class="nounderline abstract_t">Desfeux P, Camatte S, Chatellier G, et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005; 98:390.</a></li><li><a class="nounderline abstract_t">Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005; 16:403.</a></li><li><a class="nounderline abstract_t">Maneo A, Vignali M, Chiari S, et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94:387.</a></li><li><a class="nounderline abstract_t">Tropé C, Kaern J, Vergote IB, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51:236.</a></li><li><a class="nounderline abstract_t">Fort MG, Pierce VK, Saigo PE, et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32:269.</a></li><li><a class="nounderline abstract_t">Barakat RR, Benjamin I, Lewis JL Jr, et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995; 59:390.</a></li><li><a class="nounderline abstract_t">Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41:230.</a></li><li><a class="nounderline abstract_t">Shih KK, Zhou QC, Aghajanian C, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol 2010; 119:270.</a></li><li><a class="nounderline abstract_t">NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on February 08, 2019).</li><li><a class="nounderline abstract_t">Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017; 146:3.</a></li><li><a class="nounderline abstract_t">Fauvet R, Poncelet C, Boccara J, et al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005; 83:284.</a></li><li><a class="nounderline abstract_t">Chan JK, Lin YG, Loizzi V, et al. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003; 48:756.</a></li><li><a class="nounderline abstract_t">Beiner ME, Gotlieb WH, Davidson B, et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92:320.</a></li><li><a class="nounderline abstract_t">Seracchioli R, Venturoli S, Colombo FM, et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001; 76:999.</a></li><li><a class="nounderline abstract_t">Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002; 109:376.</a></li><li><a class="nounderline abstract_t">Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003; 79:1216.</a></li><li><a class="nounderline abstract_t">Tinelli FG, Tinelli R, La Grotta F, et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand 2007; 86:81.</a></li><li><a class="nounderline abstract_t">Marcickiewicz J, Brännström M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obstet Gynecol Scand 2006; 85:1496.</a></li><li><a class="nounderline abstract_t">Fasouliotis SJ, Davis O, Schattman G, et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steril 2004; 82:568.</a></li><li><a class="nounderline abstract_t">Fortin A, Morice P, Thoury A, et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007; 87:591.</a></li><li><a class="nounderline abstract_t">Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14:592.</a></li><li><a class="nounderline abstract_t">Gershenson DM. Is micropapillary serous carcinoma for real? Cancer 2002; 95:677.</a></li><li><a class="nounderline abstract_t">Kaern J, Tropé CG, Kristensen GB, et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3:349.</a></li><li><a class="nounderline abstract_t">Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002; 99:11.</a></li><li><a class="nounderline abstract_t">Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol 2005; 29:707.</a></li><li><a class="nounderline abstract_t">Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002; 86:34.</a></li><li><a class="nounderline abstract_t">Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99:3.</a></li><li><a class="nounderline abstract_t">Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47:150.</a></li><li><a class="nounderline abstract_t">Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58:2052.</a></li><li><a class="nounderline abstract_t">Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002; 95:791.</a></li><li><a class="nounderline abstract_t">Zang RY, Yang WT, Shi DR, et al. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients. J Surg Oncol 2005; 91:67.</a></li></ol></div><div id="topicVersionRevision">Topic 3181 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Blaustein's pathology of the female genital tract, 5th, Kurman RJ (Ed), Springer Verlag, New York 2002. p.791.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12959182" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathology of ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16108150" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [WHO histological classification of ovarian tumors. Geneva, 1999 (R.E.Scully, L.H.Sobin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18661518" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14682108" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ovarian tumors of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25341581" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761465" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Borderline epithelial tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885658" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Borderline ovarian tumors: current concepts for prognostic factors and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : FIGO annual report of the results of treatment in gynaecological cancer. Carcinoma of the ovary</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11352957" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216320" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Conservative surgery for borderline ovarian tumors: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15907981" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fifth International Conference on Ovarian Cancer: challenges and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368281" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436446" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306323" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Trends in incidence of borderline ovarian tumors in Denmark 1978-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22381138" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821246" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943232" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25376453" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477862" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19010876" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284991" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15893369" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037908" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hormone therapy and ovarian borderline tumors: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829372" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733975" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187051" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15619309" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Preoperative sonographic features of borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123059" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of morphology to characterize and manage common adnexal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386783" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ultrasound characteristics of different types of adnexal malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17444554" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Accuracy of ultrasound subjective 'pattern recognition' for the diagnosis of borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589572" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10836293" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349494" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognostic value of lymph node involvement in ovarian serous borderline tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15896834" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fertility and recurrence results of conservative surgery for borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11163822" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16793124" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807228" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23242913" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3173929" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685277" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical outcome and risk factors for recurrence in borderline ovarian tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical management potential tumours of low malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022280" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022280" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050549" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043215" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of surgical approach on the management of macroscopic early ovarian borderline tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653700" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Laparoscopic management of borderline ovarian tumors: results of a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297177" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Are borderline tumors of the ovary safely treated by laparoscopy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8276300" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920945" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8522261" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869100" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20719369" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7837369" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7837369" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28372871" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705364" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14619640" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11466685" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Infertility treatment after conservative management of borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704124" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12013157" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738521" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of conservative management and fertility outcome in women with borderline tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17230294" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17260228" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374697" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113086" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649107" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prognostic factors for patients with advanced stage serous borderline tumours of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209709" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is micropapillary serous carcinoma for real?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11578368" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777503" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Epithelial ovarian tumors of low malignant potential: the role of microinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897738" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt;or =5-year) follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12079297" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term survival and patterns of care in women with ovarian tumors of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777502" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468692" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term follow-up of serous ovarian tumors of low malignant potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756820" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209723" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrent micropapillary serous ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999350" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
